Search Result for : Dr Reddys

Sneha Gilada Bio Asia 2017, a global healthcare exhibition and conference, started on February 6, 2017, here in  Hyderabad. The three day event was inaugurated by the Telangana Governor ESL Narsimhan. Early into the second day of Bio Asia, packed halls witnessed eminent speakers from the pharma industry sharing their future vision for the global healthcare sector. The 14th edition of Bio Asia, as the theme suggests, was a platform for delegates, coming from more than 50 countries, to collaborate and leverage India's potential in achieving quality healthcare for billions all over the world. Dr. Paul Stoffels, Worldwide Chairman of Pharma, Johnson & Johnson(J&J) The must-attend event for any healthcare enthusiast saw participation from more than 800 corporates, and over 100 high-profile speakers. The morning session on February 7 had a special address from the likes of  Dr. Paul Stoffels, Worldwide Chairman ...

The Dollar Business Bureau What is said to be the biggest investment by an Indian pharmaceutical major in Europe following the Brexit outcome, Ahmedabad-based Intas has acquired Actavis Generics in the United Kingdom and Ireland for £600 million (around Rs.5100 crore) from Israel's Teva in an all-cash deal. A part of the European Commission's anti-trust divestiture needs emerging from Teva acquisition of Actavis Generics from Ireland-based Allergan unit for $40 billion, the transaction would enable the Indian drug major to tap a high-potential and always-growing UK and Ireland generics markets. This deal will prompt the company to undertake expansion-related initiatives, and it is expected that the company will add one more manufacturing capability to its existing three plants in the UK, ...

The Dollar Business Bureau The Indian pharma and research firm Dr Reddy's Laboratories announced the launch of generic Paricalcitol injection in the US for treatment associated with chronic kidney disease. In a filing with BSE, the company announced the launch of two injections in the 2mcg, 5mcg, and 10mcg range. This product is a generic version of AbbVie Inc’s Zemplar injections added the company in a statement.  "The injection is the first Abbreviated New Drug Application (ANDA) product launched in the US after approval from the US Food and Drug Administration," it said in the statement.  According to IMS Health the Indian pharma major’s Zemplar brand and its generic had US sales of around $22.5 million MAT for the most recent 12 months ending July ...

The Dollar Business Bureau India’s major pharmaceuticals companies are now looking to acquire niche product portfolios in several regulated markets across the world, indicated a report on Tuesday. "Recently, selected innovators have taken a call to exit their generics business and concentrate on branded/patented businesses creating billion dollar acquisition opportunities for large Indian pharma players in the regulated markets," said the report published by ICICI Securities. The country’s largest ten pharmaceutical companies, which are incidentally cash-rich, are hungry to acquire companies with their niche product portfolios. The report pointed out that the top Indian pharma companies have plethora of funds, and they can raise capital easily from debt and equity capital markets. In September, UCB sold Kremers Urban to Lannett for $1.23 billion and India-based generics portfolios ...

  The Dollar Business Bureau India’s leading drug manufacturer, Dr. Reddy’s Laboratories is gearing up for a path full of challenges in the US market. Dr. Reddy’s was denied drug approvals by the USFDA, citing underperformance on various parameters. The pharma major’s Q4 results showed the underperformance on various parameters and the challenges faced by the company. After a warning issued by USFDA regarding non-adherence to the standard manufacturing process and quality, Dr. Reddy’s is mulling plans to bring 3 plants back to India. The firm is due to send its response on measures taken to reach the expected standards to the USFDA by May. The US based plants contribute 12% of the total earnings of the firm. The firm which dominates the Indian market ...

The Dollar Business Bureau    Dr. Reddy’s Laboratories on Friday announced that it has received U.S. Food and Drug Administration (USFDA) approval for its ZEMBRACE SymTouch (sumatriptan succinate) injection. The drug-device combination product is intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regime. “ZEMBRACE SymTouch is available as a prefilled, ready to use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously,” Dr. Reddy’s said in a statement. “We are pleased to have received FDA approval for ZEMBRACE SymTouch,” said Raghav Chari, Executive Vice President, Proprietary Products group at Dr. Reddy’s Laboratory.   In many cases, ...

Both the commerce and finance ministries are currently engaged in a discussion on the issue, Pharmexcil Director General P V Appaji said Source: PTI The pharma industry is going through a crisis in Venezuela as foreign exchange controls have made repatriation of funds difficult for companies   The government is in favour of a medicines for oil barter system with Venezuela where Indian pharma exporters could not be able to repatriate their sales revenues due to restrictions imposed in that country, a senior Commerce Ministry official has said. Both the commerce and finance ministries are currently engaged in a discussion on the issue, Pharmaceuticals Export Promotion Council of India (Pharmexcil) Director General P V Appaji said. The commerce ministry is positive and in favour of ...

The Dollar Business Bureau Dr Reddy's had signed a term sheet for this transaction in September 2015. However, the agreement will be effective from July 2015   Indian drug major Dr Reddy's Laboratories on Wednesday announced that it has completed the purchase of the worldwide exclusive intellectual property rights (IPR) for Fondaparinux sodium, its generic anti-coagulant drug from its Australian partner Alchemia Ltd. worth $17.5 million. “Alchemia’s shareholders approved the sale of Fondaparinux at the company’s annual general meeting held on November 10, following which Dr Reddy’s and Alchemia have executed a purchase and sale agreement, together with various patent assignment deeds,” Dr Reddy's said in a statement. Earlier, Dr Reddy's had signed a term sheet for this transaction in September 2015. ...